




Cardarine(GW501516) Datasheet

Technical Data

Molecular Weight (MW)	453.498 g/mol	Solubility (25°C)	DMSO 78 mg/mL
Formula	C ₂₁ H ₁₈ F ₃ NO ₃ S ₂		Water <1 mg/mL
CAS No.	317318-70-0		Ethanol 78 mg/mL
Synonyms	GW501516, Cardarine	Storage	4 years -20°C Powder
			2 weeks 4°C in DMSO
			6 months -80°C in DMSO

GW501516 Chemical Structure



Return Policy

We hope this product has arrived safely with our courier. If there is a problem with your product, please contact us.

We accept returns as long as less than 20% of the product has been used and there is a problem with the substance.

We do not accept returns because of miss ordering for safety reasons.

Orders & Support

support@maxmusclelabs.com

We will contact you within one business day

Website:

maxmusclelabs.com

Biological Activity

Description	Cardarine, known as GW-501516 is a PPAR receptor agonist. It was developed by two companies, Ligand Pharma and GlaxoSmithKline					
Targets	PPAR receptor					
IC50	3.8 nM (K _i) ^[1]					
In vitro	GW 501516 decreased the IFN-γ-induced up-regulation of TNF-α and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-β agonist. However, it increased IL-6 m-RNA expression. In demyelinating cultures, reactivity of both microglial cells and astrocytes was observed, while the expression of the inflammatory cytokines and iNOS remained unaffected. [1]					
In vivo	PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxy]phenoxy]-acetic acid] and GW501516 [2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo [2]					
Clinical Trials	Discontinued					
Features	Cardarine shows promise in the treatment of insulin resistance and type 2 diabetes.					

Protocol (Only for Reference)

Kinase Assay: ^[1]

In vitro competitive radioligand binding assay	No data
--	---------

Animal Study: ^[1]

Animal Models	Immature castrated male Sprague-Dawley rats
Formulation	Dissolved in DMSO, and diluted in saline
Doses	1 mg/day
Administration	Subcutaneous injection

References

[1] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687435/>

[2] <https://www.ncbi.nlm.nih.gov/pubmed/17167170>

PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE

